z-logo
open-access-imgOpen Access
Targeted next‐generation sequencing of 22 mismatch repair genes identifies Lynch syndrome families
Author(s) -
TalsethPalmer Bente A.,
Bauer Denis C.,
Sjursen Wenche,
Evans Tiffany J.,
McPhillips Mary,
Proietto Anthony,
Otton Geoffrey,
Spigelman Allan D.,
Scott Rodney J.
Publication year - 2016
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.628
Subject(s) - lynch syndrome , indel , dna mismatch repair , nonsynonymous substitution , genetics , biology , germline mutation , clinical significance , dna sequencing , colorectal cancer , gene , cancer , mutation , medicine , genome , single nucleotide polymorphism , genotype
Causative germline mutations in mismatch repair ( MMR ) genes can only be identified in ~50% of families with a clinical diagnosis of the inherited colorectal cancer ( CRC ) syndrome hereditary nonpolyposis colorectal cancer ( HNPCC )/Lynch syndrome ( LS ). Identification of these patients are critical as they are at substantially increased risk of developing multiple primary tumors, mainly colorectal and endometrial cancer ( EC ), occurring at a young age. This demonstrates the need to develop new and/or more thorough mutation detection approaches. Next‐generation sequencing ( NGS ) was used to screen 22 genes involved in the DNA MMR pathway in constitutional DNA from 14 HNPCC and 12 sporadic EC patients, plus 2 positive controls. Several softwares were used for analysis and functional annotation. We identified 5 exonic indel variants, 42 exonic nonsynonymous single‐nucleotide variants ( SNV s) and 1 intronic variant of significance. Three of these variants were class 5 (pathogenic) or class 4 (likely pathogenic), 5 were class 3 (uncertain clinical relevance) and 40 were classified as variants of unknown clinical significance. In conclusion, we have identified two LS families from the sporadic EC patients, one without a family history of cancer, supporting the notion for universal MMR screening of EC patients. In addition, we have detected three novel class 3 variants in EC cases. We have, in addition discovered a polygenic interaction which is the most likely cause of cancer development in a HNPCC patient that could explain previous inconsistent results reported on an intronic EXO 1 variant.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom